Relmada Therapeutics, Inc.
DE ˙ DB ˙ US75955J4022
5,30 € ↓ -0,05 (-0,93%)
2026-06-04
PREZZO DELLE AZIONI
SecurityDE:4E2 / Relmada Therapeutics, Inc.
InstitutionMangrove Partners
ManagerNathaniel August
Latest Disclosed Ownership71,705 shares
Latest Disclosed Value $ 499,067
Mangrove Partners reports 161.89% increase in ownership of 4E2 / Relmada Therapeutics, Inc.

On May 15, 2026 - Mangrove Partners filed a 13F-HR form disclosing ownership of 71,705 shares of Relmada Therapeutics, Inc. (DE:4E2) valued at $394,378 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 27,380 shares of Relmada Therapeutics, Inc.. This represents a change in shares of 161.89% during the quarter. The current value of the position is $380,036 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F RELMADA THERAPEUTICS COM 75955J402 71,705 44,325 161.89 499 278.03 0.0404
2026-02-17 2025-12-31 13F RELMADA THERAPEUTICS COM 75955J402 27,380 27,380 132 0.0108
2022-08-15 2022-06-30 13F RELMADA THERAPEUTICS COM 75955J402 0 -258,094 -100.00 0 -100.00
2022-05-16 2022-03-31 13F RELMADA THERAPEUTICS COM 75955J402 258,094 125,000 93.92 6,966 132.28 0.3755
2022-02-14 2021-12-31 13F RELMADA THERAPEUTICS COM 75955J402 133,094 -26,074 -16.38 2,999 -28.12 0.1782
2021-11-15 2021-09-30 13F RELMADA THERAPEUTICS COM 75955J402 159,168 112,192 238.83 4,172 177.39 0.3733
2021-08-16 2021-06-30 13F/A-1 RELMADA THERAPEUTICS COM 75955J402 46,976 46,976 1,504 0.1548
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.